Board of Directors

_W8A8537LEVFF

Andrew Kay

Born 1955. Chairman of the Board since 2015. Member of the audit committee.

  • Education: BPharm Hons, Nottingham University.
  • Background: Andrew Kay brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as the CEO of Algeta ASA. His previous assignments include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.
  • Other current assignments: Chairman of Blueberry Therapeutics, chairman of NeRRe Therapeutics, Board advisor KaNDy Therapeutics and director of Amulet Consulting. Member of the advisory board of Odlander Fredrikson Group, the investment advisor of HealthCap´s venture funds.
  • Holdings in the Company: 7,088 shares,  255,000 stock options and 24,000 performance shares Board LTIP 2016.

Dina Chaya

Dina Chaya

Born 1971. Board Member since 2015.

  • Education: CFA charterholder, CFA Institute and BSc in natural sciences tripos, Cambridge University and MSc in development biology and PhD in molecular and cellular biology of development, Paris VI University.
  • Background: Dina Chaya is a Partner with NeoMed Management and has been investing the venture capital healthcare industry in Europe and the US since 2001. Previously, Dina worked at 3i plc in London and Index Ventures in Geneva.
  • Other current assignments: Board member of Oxular Ltd, TopiVert Ltd and TopiVert Ltd.
  • Holdings in the Company: None.

_W8A8505LEVFF

Genghis Lloyd-Harris

Born 1957. Board Member since 2014. Chairman of audit committee and member of the remuneration committee.

  • Education: MBA, Harvard University, PhD in pharmacology, University of Melbourne, MB ChB Hons in medicine and BSc Hons in biochemistry, University of Liverpool.
  • Background: Genghis Lloyd-Harris is a partner with Abingworth and joined in 2004 from Credit Suisse First Boston (CSFB) where he was a Managing Director in the European Equity Research Group based in London. Before joining Equity Research at CSFB, he worked for CSFB´s Health Care Group in the Investment Banking Division in New York. Genghis was previously a paediatrician in Melbourne, Australia.
  • Other current assignments: Board member of Abingworth LLP, Abingworth Avillion Blocker Limited, Avillion LLP and Gensight Biologics SA.
  • Holdings in the Company: 90,000 shares.

_W8A8558LEVFF

Bali Muralidhar

Born 1979. Board Member since 2014. Member of the audit committee.

  • Education: BMBCh in clinical medicine, Oxford University. MA in medical sciences and Ph.D. in cancer biology, Cambridge University.
  • Background: Bali Muralidhar is a Partner with MVM. Before joining he was a member of Bain Capital´s healthcare deal team. Prior to that he was a management consultant in Bain & Company´s healthcare team. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, Cambridge University, and has published over a dozen peer reviewed papers.
  • Other current assignments: Member of the boards of Onbone Oy, Valneva SE and Zipline Medical Inc. and is observer on the supervisory boards of Providence Medical Technology, Inc.
  • Holdings in the Company: None.

Hans Schikan

Hans Schikan

Born 1958. Board Member since 2015. Chairman of the remuneration committee.

  • Education: Pharm.D, Utrecht University.
  • Background: Hans Schikan brings more than 25 years of development, commercial and management experience, latest as the CEO of rare disease company Prosensa in The Netherlands. Mr.Schikan´s previous assignments include leading roles at Genzyme (aquired by Sanofi) and Organon (aquired by Schering Plough). At Genzyme his latest role was Vice President, Marketing & Strategic Development for the rare disease portfolio.
  • Other current assignments: Chairman of the board of Asceneuron SA, InteRNA Technologies BV and Complix NV. Board member of Swedish Orphan Biovitrum AB (publ), Hansa Medical AB (publ) and Therachon AG. Member of the Top Team of the Dutch Top Sector Life Sciences & Health. Member of the advisory board of Odlander Fredrikson Group, the investment advisor to HealthCap´s venture funds.
  • Holdings in the Company: 170,000 stock options and 16,000 performance shares Board LTIP 2016.

wilson-18-0593levff

Birgitte Volck

Born 1962. Board Member since 2017.

  • Education: MD and PhD Copenhagen University.
  • Background: Birgitte Volck currently serves as Head of R&D Rare Disease at GlaxoSmithKline. She has previously led early and late stage development programsand worked with product commercialization from pre-approval to lauch and life cycle management for companies such as Sobi, Amgen, Genzyme and Pharmexa. Birgitte has also published a number of abstracts and original papers in scientific journals.
  • Other current assignments: Senior Vice President, Head of R&D Rare Disease at GlaxoSmithKline. Board member of TFS Trial Form Support International AB and Ascendis Pharma A/S. External lecturer Copenhagen University.
  • Holdings in the Company: 20,100 performance shares Board LTIP 2017.

wilson-18-0695levf

Björn Odlander

Born 1958. Board Member since 2017. Member of the remuneration committee.

  • Education: MD and PhD, Karolinska Insitutet.
  • Background: Björn Odlander is a founder of HealthCap and serves as its Managing Partner. Previously, he pursued scientific research in the biochemistry of inflammation at Karolinska Institutet and has headed the Health Care Equity Research Team at ABB Aros Securities. Björn Odlander has extensive experience from multiple board assignments from listed and un-listed companies in the life-science sector.
  • Other current assignments: Chairman of the board of HealthCap AB. Board member and CEO for Odlander, Fredrikson & Co AB. Board member of NVC Holding AB, Oncorena AB and Bonesupport AB.
  • Holdings in the Company: None.